traveling with tirzepatide GLP-1 Medications: Semaglutide & Traveling with GLP1 Medications: Tips

Lancet Diabetes Endocrinol (2020) 8:37791

10,335,462 (462 Patent)Claim 1 (Paraphrased): A subcutaneous composition: 0.1-10 mg/mL semaglutide, phosphate/citrate/histidine buffer (pH 6.5-8.5), isotonic agent (e.g., propylene glycol), dosed weekly at 0.5/1.0 mg for T2DM.Value: Ensures stability, solubility

Our Empower tirzepatide dosing chart guide provides the exact measurements for every dose at every concentration Empower dispenses

Who Benefits Most From This Combination Therapy Patients with type 2 diabetes and a body mass index (BMI) above 27 kg/m are ideal candidates for metformin-semaglutide combination therapy, especially if monotherapy with metformin has not achieved target A1c levels